

## **GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032**

Market Report | 2024-03-02 | 134 pages | IMARC Group

### **AVAILABLE LICENSES:**

- Electronic (PDF) Single User \$3699.00
- Five User Licence \$4699.00
- Enterprisewide License \$5699.00

### **Report description:**

The GCC generic drug market size reached US\$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 14.7 Billion by 2032, exhibiting a growth rate (CAGR) of 10.6% during 2024-2032.

Generic drugs are bioequivalent of branded medicines, which have similar dosages, risks, effects, side effects, strengths, intended use and route of administration. They also have identical active ingredients and are relatively less expensive than their branded counterparts, as they do not require extensive research or testing. Nonetheless, their color and shape may differ from the original drug as altering these characteristics does not impact the effectiveness of the medicine. At present, there is a rise in the demand for generic drugs in the GCC region, owing to the developing healthcare industry and the growing awareness about the cost benefits offered by these drugs.

Owing to sedentary lifestyles, high per capita income and altering dietary patterns, there is a significant increase in the prevalence of lifestyle and chronic diseases, such as cancer, diabetes and obesity, in the GCC region. This represents one of the key factors impelling the generic drugs market growth in the region. Moreover, the growing geriatric population is also contributing to the increasing healthcare costs in the region. In line with this, governments of various countries in the GCC region, such as Oman and the United Arab Emirates (UAE), are encouraging the utilization of generic drugs, which is further bolstering the market growth. For instance, the Government of Oman recently introduced the Unified Health Insurance Policy (UHIP) that made health insurance mandatory for citizens and expatriates. It is catalyzing the demand for pharmaceuticals in the country which, in turn, is driving investments for generics manufacturing. Some of the other factors that are propelling the market growth include growing population, increasing penetration of health insurance companies, upcoming patent expiry of various blockbuster medicines and a strong influx of expatriates.

### **Key Market Segmentation:**

IMARC Group provides an analysis of the key trends in each sub-segment of the GCC generic drug market report, along with

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

forecasts at the regional and country level from 2024-2032.

#### Regional Insights:

Saudi Arabia

United Arab Emirates (UAE)

Kuwait

Qatar

Bahrain

Oman

On the geographical front, Saudi Arabia represents the largest market for generic drugs in the GCC region. The large population in the country represents a key driving factor for the market. Moreover, the Government of Saudi Arabia is promoting joint ventures and sponsoring non-tariff barriers for pharmaceutical manufacturing in the country, which is further projected to accelerate the industry growth.

#### Competitive Landscape:

The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry.

#### Key Questions Answered in This Report:

How has the GCC generic drugs market performed so far and how will it perform in the coming years?

What are the key regional segments in the industry?

What has been the impact of COVID-19 on the GCC generic drugs market?

What are the price trends of generic drugs?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the industry and who are the key players?

What is the degree of competition in the GCC generic drugs industry?

What are the profit margins in the GCC generic drugs industry?

What are the key requirements for setting up a generic drugs manufacturing plant?

How are generic drugs manufactured?

What are the various unit operations involved in a generic drugs manufacturing plant?

What is the total size of land required for setting up a generic drugs manufacturing plant?

What are the machinery requirements for setting up a generic drugs manufacturing plant?

What are the raw material requirements for setting up a generic drugs manufacturing plant?

What are the packaging requirements for generic drugs?

What are the transportation requirements for generic drugs?

What are the utility requirements for setting up a generic drugs manufacturing plant?

What are the manpower requirements for setting up a generic drugs manufacturing plant?

What are the infrastructure costs for setting up a generic drugs manufacturing plant?

What are the capital costs for setting up a generic drugs manufacturing plant?

What are the operating costs for setting up a generic drugs manufacturing plant?

What will be the income and expenditures for a generic drugs manufacturing plant?

What is the time required to break-even?

#### Table of Contents:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 1 Preface
- 2 Scope and Methodology
  - 2.1 Objectives of the study
  - 2.2 Stakeholders
  - 2.3 Data Sources
    - 2.3.1 Primary Sources
    - 2.3.2 Secondary Sources
  - 2.4 Market Estimation
    - 2.4.1 Bottom-Up Approach
    - 2.4.2 Top-Down Approach
  - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
  - 4.1 Overview
  - 4.2 Key Industry Trends
- 5 Global Generic Drug Industry
  - 5.1 Market Overview
  - 5.2 Market Performance
  - 5.3 Market Breakup by Region
  - 5.4 Market Breakup by Drug Delivery
  - 5.5 Market Forecast
- 6 GCC Generic Drug Industry
  - 6.1 Market Overview
  - 6.2 Market Performance
  - 6.3 Impact of COVID-19
  - 6.4 Market Breakup by Region
  - 6.5 Market Forecast
  - 6.6 SWOT Analysis
    - 6.6.1 Overview
    - 6.6.2 Strengths
    - 6.6.3 Weaknesses
    - 6.6.4 Opportunities
    - 6.6.5 Threats
  - 6.7 Value Chain Analysis
    - 6.7.1 Overview
    - 6.7.2 Research and Development
    - 6.7.3 Raw Material Procurement
    - 6.7.4 Manufacturing
    - 6.7.5 Marketing
    - 6.7.6 Distribution
  - 6.8 Porter's Five Forces Analysis
    - 6.8.1 Overview
    - 6.8.2 Bargaining Power of Buyers
    - 6.8.3 Bargaining Power of Suppliers
    - 6.8.4 Degree of Competition
    - 6.8.5 Threat of New Entrants
    - 6.8.6 Threat of Substitutes

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.9 Key Success and Risk Factors for Manufacturers
- 7 Performance of Key Regions
  - 7.1 Saudi Arabia
    - 7.1.1 Market Performance
    - 7.1.2 Market Forecast
    - 7.1.3 Key Players
    - 7.1.4 Regulatory Process for Generics Drug Industry in Saudi Arabia
  - 7.2 UAE
    - 7.2.1 Market Performance
    - 7.2.2 Market Forecast
    - 7.2.3 Key Players
    - 7.2.4 Regulatory Process for Generics Drug Industry in UAE
  - 7.3 Kuwait
    - 7.3.1 Market Performance
    - 7.3.2 Market Forecast
    - 7.3.3 Regulatory Process for Generics Drug Industry in Kuwait
  - 7.4 Qatar
    - 7.4.1 Market Performance
    - 7.4.2 Market Forecast
    - 7.4.3 Regulatory Process for Generics Drug Industry in Qatar
  - 7.5 Bahrain
    - 7.5.1 Market Performance
    - 7.5.2 Market Forecast
    - 7.5.3 Regulatory Process for Generics Drug Industry in Bahrain
  - 7.6 Oman
    - 7.6.1 Market Performance
    - 7.6.2 Market Forecast
    - 7.6.3 Regulatory Process for Generics Drug Industry in Oman
- 8 Competitive Landscape
  - 8.1 Market Structure
  - 8.2 Market Share of Key Players
- 9 Generic Drug Manufacturing Process
  - 9.1 Product Overview
  - 9.2 Detailed Process Flow
  - 9.3 Various Types of Unit Operations Involved
  - 9.4 Mass Balance and Raw Material Requirements
- 10 Project Details, Requirements and Costs Involved
  - 10.1 Land Requirements and Expenditures
  - 10.2 Construction Requirements and Expenditures
  - 10.3 Plant Machinery
  - 10.4 Machinery Pictures
  - 10.5 Raw Material Requirements and Expenditures
  - 10.6 Packaging Requirements and Expenditures
  - 10.7 Transportation Requirements and Expenditures
  - 10.8 Utility Requirements and Expenditures
  - 10.9 Manpower Requirements and Expenditures
  - 10.10 Other Capital Investments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11 Loans and Financial Assistance
- 12 Project Economics
  - 12.1 Capital Cost of the Project
  - 12.2 Techno-Economic Parameters
  - 12.3 Product Pricing and Margins across Various Levels of the Supply Chain
  - 12.4 Taxation and Depreciation
  - 12.5 Income Projections
  - 12.6 Expenditure Projections
  - 12.7 Financial Analysis
  - 12.8 Profit Analysis
- 13 Key Player Profiles

## GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032

Market Report | 2024-03-02 | 134 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$3699.00
	Five User Licence	\$4699.00
	Enterprisewide License	\$5699.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-04"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)